SGC Stockholm has been
wound down as of July 1 2011.
and chemical biology to explore epigenetic signalling (follow on project)
SGC Stockholm Structure Gallery
SGC Stockholm Publications
poster for download (pdf)
infrastructure for high-throughput protein production and protein
crystallography is now available to external users in the form of a Protein Science Facility affiliated to
Science for Life Laboratory.
Links to information
on SGC science programs and follow-on projects are found below.
Structural Genomics Consortium (SGC)
is a not-for-profit
organization that aims to determine the three dimensional structures of
proteins of medical relevance, and place them in the public domain
restriction. The SGC operates out of the Universities of Oxford
Institutet, Stockholm. During the first phase of
the project, more
than 450 protein structures
were deposited in the PDB.
The goal of 660 additional structures in the second funding phase (July
- June 30 2011) will be reached early spring 2011. SGC works on a Target List of
relevance to human health comprising
proteins associated with diabetes, cancer, genetic and epigenetic
well as with infectious
diseases such as malaria.
laboratory was established in 2005 after funding
provided by the Swedish Foundation for Strategic Research (SSF), the
Alice Wallenberg foundation (KAW), the
Governmental Agency for Innovation Systems
(VINNOVA) and Karolinska Institutet. The laboratory is hosted by the Department
of Medical Biochemistry and Biophysics
Institutet. Currently the activities of SGC Stockholm are being wound
down, in the absence of continued funding support beyond June 30, 2011.
Genomics and Impact for Society
deposited its 1000th
official structure into the Protein Data Bank in July 2010. The
amount of structural information generated by the SGC
is expected to have a tremendous impact on human health by furthering
understanding of relevant proteins - leading to new hypotheses and new
directions for biomedicinal research - and by supplying new targets for
therapeutic intervention. It will also provide the structural framework
rational design of new or improved drugs that can inhibit or enhance
significant contributions of structural biology to drug discovery are
documented (e.g. http://publications.nigms.nih.gov/structlife/chapter4.html).